Inogen (NASDAQ:INGN – Get Free Report) posted its earnings results on Tuesday. The medical technology company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.14, Briefing.com reports. The business had revenue of $78.03 million during the quarter, compared to analyst estimates of $73.67 million. Inogen had a negative return on equity of 38.98% and a negative net margin of 32.46%. The company’s revenue for the quarter was up 8.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.63) earnings per share.
Inogen Price Performance
INGN traded up $0.12 on Friday, reaching $8.81. The company’s stock had a trading volume of 24,313 shares, compared to its average volume of 525,915. Inogen has a 1 year low of $4.13 and a 1 year high of $11.98. The business’s 50 day moving average is $7.15 and its 200 day moving average is $6.53. The stock has a market cap of $207.45 million, a price-to-earnings ratio of -1.97 and a beta of 1.10.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on the company. Stifel Nicolaus upped their price target on Inogen from $6.00 to $7.00 and gave the stock a “hold” rating in a report on Wednesday. William Blair upgraded shares of Inogen from a “market perform” rating to an “outperform” rating in a research note on Thursday, February 15th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Inogen in a report on Wednesday. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Inogen has a consensus rating of “Hold” and an average target price of $7.00.
About Inogen
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Read More
- Five stocks we like better than Inogen
- What is Forex and How Does it Work?
- JFrog Stock Gets Punished for Solid Results: Buy the Dip
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Will the Surge in GameStop Stock Spark a New Meme Craze?
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- 3 Stocks Nancy Pelosi Has Been Buying
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.
